Age-related Macular Degeneration (AMD) Market Overview
As per Econ Market Research analysis, the Global Age-related Macular Degeneration (AMD) Market valuation stood at US$ 12.45 Billion in 2026 and is expected to reach US$ 24.03 Billion by 2035, growing at a steady CAGR of 7.5% from 2026 to 2035. 2025 serves as the base year.
Age-related Macular Degeneration (AMD) is a progressive eye condition characterized by the deterioration of the macula, a small area in the center of the retina responsible for sharp, central vision. This degenerative process primarily affects individuals aged 50 and older, leading to a gradual loss of central vision and potentially severe visual impairment. AMD is categorized into two types: dry AMD, marked by the accumulation of drusen (yellow deposits) in the macula, and wet AMD, characterized by the growth of abnormal blood vessels beneath the macula, often resulting in leakage and scarring.
Because of rising awareness, an ageing population, and improvements in diagnostic and treatment technologies, the global market for age-related macular degeneration has grown significantly in recent years. To address the unmet medical needs of AMD patients, major players in the market are actively developing novel treatment approaches, such as gene therapies and anti-VEGF therapies. Research and development efforts targeting the exploration of possible biomarkers for early detection and customised treatment approaches are also on the rise in the market.
Age-related Macular Degeneration (AMD) Dynamics
The aging global population is a primary driver, as individuals aged 50 and above, who are more susceptible to AMD, constitute a growing demographic. Additionally, the increasing prevalence of lifestyle-related factors, such as poor diet and sedentary lifestyles, contributes to the rising incidence of AMD. Technological advancements in diagnostic tools, such as optical coherence tomography (OCT) and fundus imaging, enable early detection and monitoring, fostering market growth. In terms of therapeutics, ongoing R&,D initiatives to introduce cutting-edge treatment modalities are driving the market. Wet AMD management is dominated by anti-VEGF therapies, with new drug candidates being explored in ongoing clinical trials.
The industry',s dedication to expanding treatment options is demonstrated by the emergence of gene therapies, Regenerative Medicine, and combination therapies as viable paths forward. There are still issues, though, such as the high expense of medical care, the difficulty in accessing cutting-edge therapies, and the requirement for personalised medicine techniques. These elements give market participants the chance to investigate pricing tactics, broaden their consumer base, and work together on projects that improve patient accessibility and affordability. In general, the AMD market is defined by the dynamic interaction of changing demographics, advances in technology, and novel therapeutics, requiring industry participants to be flexible and strategically positioned.
Age-related Macular Degeneration (AMD) Drivers
Aging Population and Increased Incidence of AMD
The market for age-related macular degeneration (AMD) is heavily influenced by the growing number of people over 50 in the world. Given that age is the main risk factor for AMD, the number of elderly people in the population is growing, which adds to the condition',s increased prevalence. The market is growing as a result of this shift in demographics, which increases demand for AMD diagnostics and treatments. The growing number of possible patients emphasises how crucial it is to carry out more research and development to meet the unique requirements of this elderly population.
Technological Advancements in Diagnosis and Treatment
The market for AMD is largely driven by ongoing developments in diagnostic technologies, including fundus imaging and optical coherence tomography (OCT). These instruments facilitate prompt intervention by enabling early detection, precise diagnosis, and tracking of AMD progression. Furthermore, advancements in therapeutic approaches, specifically the triumph of anti-VEGF medications, have revolutionised the field of managing AMD. The emergence of regenerative medicine and gene therapies expands the range of available treatments and opens up new directions for individualised and focused care. The ongoing development of these technologies boosts AMD diagnosis and treatment efficacy and efficiency, which supports market growth.
Restraints:
High Treatment Costs and Limited Accessibility
The market growth is severely limited by the high cost of AMD treatments, especially anti-VEGF therapies. There are differences in the availability of treatment due to the financial strain on patients and healthcare systems that restricts access to these cutting-edge therapies. For market participants, addressing the affordability issue is critical. To guarantee that more patients have access to state-of-the-art AMD treatments, strategic pricing models, partnerships, and advocacy initiatives are needed.
Long-term Management Challenges
AMD requires ongoing care, including ongoing therapeutic interventions and routine monitoring. This creates problems for patient adherence and puts a burden on medical resources needed for ongoing treatment administration and follow-up. The intricacy of long-term care is increased by the frequent injections required by anti-VEGF treatments. To improve treatment adherence and lessen the burden on patients and healthcare systems, overcoming these obstacles requires creating more practical and patient-friendly treatment regimens in addition to innovations in sustained-release formulations.
Opportunities:
Personalized Medicine and Targeted Therapies
The emerging field of personalized medicine offers a significant opportunity for the AMD market. As our understanding of the genetic and molecular basis of AMD expands, there is a growing potential for developing targeted therapies tailored to individual patient profiles. Precision medicine approaches can optimize treatment outcomes by considering genetic factors, biomarkers, and patient-specific characteristics, leading to more effective and personalized interventions for AMD.
Segment Overview
By Type
The market is classified into two primary types of AMD: Dry AMD and Wet AMD. Dry AMD is characterized by the gradual deterioration of light-sensitive cells in the macula, leading to a slow and progressive loss of central vision. On the other hand, Wet AMD involves the abnormal growth of blood vessels beneath the macula, leading to a more rapid and severe decline in vision. Both types present unique challenges in terms of diagnosis, treatment, and patient care, necessitating targeted approaches for each subtype.
By End User
The end-user segment encompasses a diverse range of healthcare settings where AMD diagnosis and treatment take place. This includes Hospitals, where a comprehensive range of medical services are provided, Specialty Clinics, which focus specifically on ophthalmic care and AMD management, Ambulatory Surgical Centers, offering outpatient surgical procedures related to AMD, Home Healthcare, facilitating patient care within the comfort of their homes, and Others, representing various healthcare facilities involved in AMD management. Each end-user category plays a crucial role in delivering AMD-related services, emphasizing the need for tailored strategies to meet the specific requirements of each setting.
By Distribution Channel
The distribution channel segment highlights the pathways through which AMD-related products and treatments reach end-users. Direct Tender involves procurement processes initiated by healthcare institutions to directly acquire medications and services. Retail Sales encompass over-the-counter purchases made by consumers seeking AMD-related products from pharmacies or other retail outlets. Efficient distribution channels are essential to ensure timely access to AMD treatments, and understanding the dynamics of these channels is vital for optimizing the reach and impact of AMD management solutions.
Age-related Macular Degeneration (AMD) Overview by Region
In North America, the market is characterized by a high prevalence of AMD cases, driven by an aging population and advanced diagnostic capabilities. The presence of well-established healthcare facilities, coupled with substantial investments in research and development, positions North America as a key player in the AMD market. Europe follows a similar trajectory, with a significant aging population contributing to a rising incidence of AMD. Access to advanced medical technologies and robust healthcare systems in Western European countries further amplifies the regional market',s growth.
Asia-Pacific emerges as a dynamic market for AMD, driven by the increasing elderly population, changing lifestyle factors, and improving healthcare infrastructure. Rapid urbanization and lifestyle shifts contribute to the rising prevalence of AMD in countries like China and India. Additionally, the Asia-Pacific region witnesses a surge in healthcare awareness and adoption of advanced treatments, fostering market expansion. In contrast, Latin America and the Middle East &, Africa regions face unique challenges, including limited access to healthcare services and lower awareness levels about AMD. However, growing efforts to enhance healthcare infrastructure and raise awareness about eye health are gradually influencing the market dynamics in these regions.
Age-related Macular Degeneration (AMD) Market Competitive Landscape
Leading pharmaceutical companies such as Novartis, Roche, and Regeneron Pharmaceuticals play a pivotal role in driving innovation and dominating the AMD therapeutics sector. These companies focus on research and development activities to introduce novel drugs and therapies, often leveraging partnerships with academic institutions and smaller biotech firms to bolster their pipelines.
In addition to pharmaceutical giants, medical device manufacturers like Bausch + Lomb and Genentech contribute significantly to the competitive landscape, developing cutting-edge diagnostic tools and equipment for early AMD detection and precise monitoring. The competitive scenario is further enriched by the presence of specialized Biotechnology firms, such as Ophthotech Corporation and Apellis Pharmaceuticals, dedicated to addressing specific challenges associated with AMD treatment. These companies often emphasize targeted therapeutic approaches, including gene therapies and complement inhibition, showcasing the industry',s commitment to diversifying treatment modalities.
Age-related Macular Degeneration (AMD) Market Leading Companies:
Novartis AG
Bayer AG
Regeneron Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd
Pfizer Inc.
Amgen Inc.
Bausch Health Companies Inc.
Age-related Macular Degeneration (AMD) Recent Developments
Dec 2023, TruTag Technologies, Inc. and Spinnaker Biosciences, Inc. have recently formed a strategic supply partnership. This collaboration aims to leverage TruTag',s advanced nano-porous silica (pSi) particles in the development and commercialization of Spinnaker',s innovative therapy designed for treating age-related macular degeneration (AMD).
Aug 2023, Astellas Pharma Inc. LED by President and CEO Naoki Okamura, announced today that the U.S. Food and Drug Administration (FDA) has granted approval for IZERVAY (avacincaptad pegol intravitreal solution) as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on August 4, 2023. IZERVAY, a novel complement C5 inhibitor, stands out as the sole GA treatment endorsed by the FDA, demonstrating a statistically significant reduction (p<,0.01) in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.
Global Age-related Macular Degeneration (AMD) Report Segmentation
Age-related Macular Degeneration (AMD) Market Segmentation
| Segment Category | Segment Values |
|---|---|
| Drug Type |
|
| Disease Type |
|
| Distribution Channel |
|
Key Players
- Regeneron
- Novartis
- F. Hoffmann-La Roche
- Bayer
- Apellis Pharmaceuticals
- Iveric Bio (Astellas)
- Outlook Therapeutics
Table of Contents
1. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET–REPORT OVERVIEW
- 1.1. SCOPE OF THE REPORT
- 1.2. MARKET SEGMENT ANALYSIS
- 1.3. REGULATORY SCENARIO BY REGION/COUNTRY
- 1.4. MARKET INVESTMENT SCENARIO STRATEGIC
- 1.5. MARKET ANALYSIS BY BY DRUG TYPE (USD MILLION)
- 1.5.1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY BY DRUG TYPE (2026-2035)
- 1.5.2 EYLEA
- 1.5.3 LUCENTIS
- 1.5.4 BEOVU
- 1.5.5 OTHERS
- 1.6. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY BY DRUG TYPE IN 2026 & 2035
- 1.7. MARKET ANALYSIS BY BY DISEASE TYPE (USD MILLION)
- 1.7.1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY BY DISEASE TYPE (2026-2035)
- 1.7.2 WET AMD
- 1.7.3 DRY AMD
- 1.8. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY BY DISEASE TYPE IN 2026 & 2035
- 1.9. MARKET ANALYSIS BY BY DISTRIBUTION CHANNEL (USD MILLION)
- 1.9.1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY BY DISTRIBUTION CHANNEL (2026-2035)
- 1.9.2 HOSPITAL PHARMACIES
- 1.9.3 RETAIL PHARMACIES
- 1.9.4 ONLINE PHARMACIES
- 1.10. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY BY DISTRIBUTION CHANNEL IN 2026 & 2035
2. DRIVER RESTRAINT CHALLENGE AND OPPORTUNITIES OF AGE-RELATED MACULAR DEGENERATION (AMD) MARKET
- 2.1. DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
- 2.1.1 MARKET DRIVER ANALYSIS
- 2.1.2 MARKET RESTRAINT ANALYSIS
- 2.1.3 MARKET OPPORTUNITY
- 2.2. MARKET CHALLENGES
3. GLOBAL GROWTH TRENDS
- 3.1. INDUSTRY TRENDS
- 3.1.1 SWOT ANALYSIS
- 3.1.1.1 Strengths
- 3.1.1.2 Weaknesses
- 3.1.1.3 Opportunities
- 3.1.1.4 Threats
- 3.1.2 PESTEL ANALYSIS
- 3.1.2.1 Political Landscape
- 3.1.2.2 Economic Landscape
- 3.1.2.3 Social Landscape
- 3.1.2.4 Technological Landscape
- 3.1.2.5 Environmental Landscape
- 3.1.2.6 Legal Landscape
- 3.1.3 PORTER'S FIVE FORCES ANALYSIS
- 3.1.3.1 Bargaining Power of Suppliers
- 3.1.3.2 Bargaining Power of Buyers
- 3.1.3.3 Threat of Substitute
- 3.1.3.4 Threat of New Entrant
- 3.1.3.5 Competitive Rivalry
- 3.1.1 SWOT ANALYSIS
- 3.2. POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4. POST COVID ANALYSIS
- 4.1. COVID V ANALYSIS
- 4.2. COVID U ANALYSIS
- 4.3. COVID L ANALYSIS
- 4.4. COVID W ANALYSIS
5. COMPANIES ANALYSIS
- 5.1. PLAYERS COVERED: RANKING BY AGE-RELATED MACULAR DEGENERATION (AMD) MARKET REVENUE
- 5.2. TOP COMPANIES MARKET SHARE (%)
6. EXECUTIVE SUMMARY
7. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET FORECAST, 2022-2035, (USD MILLION)
- 7.1. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET REVENUE AND MARKET SHARE BY REGIONS
- 7.2. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY REGION (2022-2029)
- 7.3. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY REGION (2030-2035)
- 7.3.1.1 North America
- 7.3.1.2 Europe
- 7.3.1.3 Asia Pacific
- 7.3.1.4 Latin America
- 7.3.1.5 Middle East & Africa
8. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 8.1. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 8.2. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 8.3. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 8.3.1.1 United States
- 8.3.1.2 Canada
- 8.3.1.3 Mexico
9. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 9.1. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 9.2. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 9.3. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 9.3.1.1 United Kingdom
- 9.3.1.2 Germany
- 9.3.1.3 France
- 9.3.1.4 Spain
- 9.3.1.5 Italy
- 9.3.1.6 Rest of Europe
10. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 10.1. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 10.2. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 10.3. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 10.3.1.1 China
- 10.3.1.2 India
- 10.3.1.3 Japan
- 10.3.1.4 Australia
- 10.3.1.5 South Korea
- 10.3.1.6 Rest of Asia Pacific
11. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 11.1. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 11.2. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 11.3. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 11.3.1.1 Saudi Arabia
- 11.3.1.2 South Africa
- 11.3.1.3 Rest of MEA
12. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 12.1. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 12.2. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 12.3. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 12.3.1.1 Brazil
- 12.3.1.2 Argentina
- 12.3.1.3 Rest of Latin America
13. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SEGMENT BY BY DRUG TYPE, (USD MILLION)
- 13.1. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.2. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
- 13.3. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.4. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
- 13.5. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.6. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
- 13.7. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.8. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
- 13.9. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.10. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
- 13.11. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.12. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
13. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SEGMENT BY BY DISEASE TYPE, (USD MILLION)
- 13.13. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2022-2029)
- 13.14. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2030-2035)
- 13.15. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2022-2029)
- 13.16. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2030-2035)
- 13.17. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2022-2029)
- 13.18. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2030-2035)
- 13.19. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2022-2029)
- 13.20. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2030-2035)
- 13.21. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2022-2029)
- 13.22. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2030-2035)
- 13.23. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2022-2029)
- 13.24. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISEASE TYPE (2030-2035)
13. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SEGMENT BY BY DISTRIBUTION CHANNEL, (USD MILLION)
- 13.25. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.26. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
- 13.27. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.28. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
- 13.29. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.30. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
- 13.31. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.32. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
- 13.33. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.34. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
- 13.35. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.36. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
14. COMPANY PROFILES
- 14.1. REGENERON
- 14.1.1 COMPANY DETAIL
- 14.1.2 FINANCIALS (USD MILLIONS)
- 14.1.3 PRODUCT SUMMARY
- 14.1.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.2. NOVARTIS
- 14.2.1 COMPANY DETAIL
- 14.2.2 FINANCIALS (USD MILLIONS)
- 14.2.3 PRODUCT SUMMARY
- 14.2.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.3. F. HOFFMANN-LA ROCHE
- 14.3.1 COMPANY DETAIL
- 14.3.2 FINANCIALS (USD MILLIONS)
- 14.3.3 PRODUCT SUMMARY
- 14.3.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.4. BAYER
- 14.4.1 COMPANY DETAIL
- 14.4.2 FINANCIALS (USD MILLIONS)
- 14.4.3 PRODUCT SUMMARY
- 14.4.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.5. APELLIS PHARMACEUTICALS
- 14.5.1 COMPANY DETAIL
- 14.5.2 FINANCIALS (USD MILLIONS)
- 14.5.3 PRODUCT SUMMARY
- 14.5.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.6. IVERIC BIO (ASTELLAS)
- 14.6.1 COMPANY DETAIL
- 14.6.2 FINANCIALS (USD MILLIONS)
- 14.6.3 PRODUCT SUMMARY
- 14.6.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.7. OUTLOOK THERAPEUTICS
- 14.7.1 COMPANY DETAIL
- 14.7.2 FINANCIALS (USD MILLIONS)
- 14.7.3 PRODUCT SUMMARY
- 14.7.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
15. CONCLUSION
16. REFERENCE LINK
17. APPENDIX
- 17.1. METHODOLOGY
- 17.2. RESEARCH DATA SOURCE
- 17.2.1 SECONDARY DATA
- 17.2.2 KEY DATA FROM SECONDARY
- 17.2.3 PRIMARY DATA
- 17.2.4 KEY DATA FROM PRIMARY
- 17.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
- 17.2.6 MARKET ESTIMATION
- 17.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
- 17.2.8 LEGAL DISCLAIMER
18. RESEARCH SCOPE
LIST OF TABLES
- TABLE 1. MARKET SEGMENT
- TABLE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET GROWTH RATE BY BY DRUG TYPE (2026-2035)
- TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET GROWTH RATE BY BY DISEASE TYPE (2026-2035)
- TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET GROWTH RATE BY BY DISTRIBUTION CHANNEL (2026-2035)
- TABLE 5. COMPANY'S RANK BY AGE-RELATED MACULAR DEGENERATION (AMD) MARKET REVENUE
- TABLE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET — MARKET SNAPSHOT & KEY BUYING CRITERIA, 2026–2035
- TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY REGION, USD MILLION (2022-2029)
- TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY REGION, (2022-2029)
- TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY REGION, USD MILLION (2030-2035)
- TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY REGION, (2030-2035)
- TABLE 13. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 14. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 15. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 16. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 17. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 18. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 19. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 20. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 21. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 22. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 23. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY COUNTRY, (2022-2029)
- TABLE 24. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 25. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY COUNTRY, (2030-2035)
- TABLE 26. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 27. UNITED STATES AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 28. UNITED STATES AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 29. CANADA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 30. CANADA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 31. MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 32. MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 33. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY COUNTRY, (2022-2029)
- TABLE 34. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 35. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY COUNTRY, (2030-2035)
- TABLE 36. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 37. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 38. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 39. GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 40. GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 41. FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 42. FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 43. SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 44. SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 45. ITALY AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 46. ITALY AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 47. REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 48. REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 49. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY COUNTRY, (2022-2029)
- TABLE 50. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 51. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY COUNTRY, (2030-2035)
- TABLE 52. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 53. CHINA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 54. CHINA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 55. INDIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 56. INDIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 57. JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 58. JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 59. AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 60. AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 61. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 62. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 63. REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 64. REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 65. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY COUNTRY, (2022-2029)
- TABLE 66. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 67. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY COUNTRY, (2030-2035)
- TABLE 68. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 69. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 70. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 71. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 72. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 73. REST OF MEA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 74. REST OF MEA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 75. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY COUNTRY, (2022-2029)
- TABLE 76. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 77. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY COUNTRY, (2030-2035)
- TABLE 78. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 79. BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 80. BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 81. ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 82. ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 83. REST OF LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2022-2029)
- TABLE 84. REST OF LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (USD MILLION) (2030-2035)
- TABLE 85. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 86. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 87. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 88. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 89. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 90. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 91. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 92. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 93. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 94. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 95. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 96. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 97. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2022-2029)
- TABLE 98. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2030-2035)
- TABLE 99. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2022-2029)
- TABLE 100. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2030-2035)
- TABLE 101. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2022-2029)
- TABLE 102. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2030-2035)
- TABLE 103. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2022-2029)
- TABLE 104. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2030-2035)
- TABLE 105. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2022-2029)
- TABLE 106. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2030-2035)
- TABLE 107. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2022-2029)
- TABLE 108. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISEASE TYPE, USD MILLION (2030-2035)
- TABLE 109. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 110. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
- TABLE 111. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 112. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
- TABLE 113. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 114. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
- TABLE 115. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 116. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
- TABLE 117. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 118. MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
- TABLE 119. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 120. SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
LIST OF FIGURES
- FIGURE 1. MARKET OVERVIEW
- FIGURE 2. REGIONAL SHARE
- FIGURE 3. MARKET REVENUE (USD MILLION)
- FIGURE 4. DROC OF AGE-RELATED MACULAR DEGENERATION (AMD) MARKET ANALYSIS
- FIGURE 5. SWOT ANALYSIS
- FIGURE 6. PESTEL ANALYSIS
- FIGURE 7. PORTER'S FIVE FORCES ANALYSIS
- FIGURE 8. COVID V, U, W AND L ANALYSIS
- FIGURE 9. LEADING COMPANIES
- FIGURE 10. REGIONAL ANALYSIS
- FIGURE 11. COUNTRY ANALYSIS
- FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION), BY REGION
- FIGURE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2026), BY REGION
- FIGURE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION), BY REGION
- FIGURE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2035), BY REGION
- FIGURE 18. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 19. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 20. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 21. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 22. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 23. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 24. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 25. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 26. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 27. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 28. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 29. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2026), BY COUNTRY
- FIGURE 30. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 31. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2035), BY COUNTRY
- FIGURE 32. UNITED STATES AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 33. UNITED STATES AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 34. CANADA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 35. CANADA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 36. MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 37. MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 38. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 39. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2026), BY COUNTRY
- FIGURE 40. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 41. EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2035), BY COUNTRY
- FIGURE 42. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 43. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 44. GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 45. GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 46. FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 47. FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 48. SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 49. SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 50. ITALY AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 51. ITALY AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 52. REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 53. REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 54. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 55. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2026), BY COUNTRY
- FIGURE 56. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 57. ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2035), BY COUNTRY
- FIGURE 58. CHINA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 59. CHINA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 60. INDIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 61. INDIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 62. JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 63. JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 64. AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 65. AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 66. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 67. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 68. REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 69. REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 70. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 71. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2026), BY COUNTRY
- FIGURE 72. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 73. MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2035), BY COUNTRY
- FIGURE 74. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 75. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 76. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 77. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 78. REST OF MEA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 79. REST OF MEA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 80. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 81. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2026), BY COUNTRY
- FIGURE 82. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 83. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SHARE, (2035), BY COUNTRY
- FIGURE 84. BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 85. BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 86. ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 87. ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
- FIGURE 88. REST OF LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2022-2029), (USD MILLION)
- FIGURE 89. REST OF LATIN AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, (2030-2035), (USD MILLION)
Research Methodology
Our research methodology is carefully designed to deliver the clients with the most accurate, relevant, and actionable market insights to enable clear decision-making and leveraging of opportunities in the markets. We believe consistency, depth in analysis, and a tailored approach in each report are what help set us apart in the industry. The research methodology is based on an integrating research process consisting of in-depth data collection, a complex analysis, and a stringent validation system.
Data Collection
Data collection forms the basis of our study and gathers diverse authentic data to build the basis for deeper study in terms of market trends, competitive landscape, and growth prospects. Data collection takes place through two channels of main activities as follows:
Primary Data Collection
Primary data collection allows collecting real-time and firsthand information from market participants. This is an engagement process conducted by our team with other industry stakeholders, where a much deeper insight than any published data is pursued. This process includes:
- Direct Interviews – We interview the key decision-makers such as CEOs, product managers, innovation heads, and marketing directors to gather both qualitative and quantitative information. The questionnaire covers emerging trends, customer preferences, regulatory impact, and competitors’ strategies.
- Demand and Supply-Side Inputs – Interviews and surveys with supply and demand-side stakeholders provide a balanced view of prevailing market conditions, including feedback from manufacturers, distributors, suppliers, and end-users.
- Expert Opinions – Consultations with industry experts and domain specialists provide insights into future market direction, risks, and opportunities.
- Focus Groups and Online Surveys – Focus groups and surveys are used to understand consumer preferences and adoption probability of new products or services.
Primary research forms the core of our data validation process by offering direct insights into the market, addressing limitations in secondary data, and allowing for an adaptable research process.
Secondary Data Collection
Secondary research serves as a robust foundation for understanding market context, historical data, and larger trends. It involves systematic gathering of existing information from verified sources.
- Industry Reports and Publications – Market reports, white papers, and case studies from credible sources provide a broad view of the market landscape and key players.
- Government and Public Records – Data from government agencies and regulatory bodies helps analyze economic factors and policy impacts.
- News and Media Outlets – Monitoring news articles, press releases, and media reports keeps us updated on market developments and M&A activity.
- Proprietary and Paid Databases – Databases such as Bloomberg, Factiva, D&B Hoovers, and Thomson Reuters provide validated and cross-referenced data.
- Financial Reports and SEC Filings – Financial statements, annual reports, and investor presentations provide insights into revenue structures and profitability.
This combination of primary and secondary data sources enables us to provide a comprehensive view of the market, supported by authenticated information across multiple sources.
Data Analysis Techniques
With the data collected, we initiate a rigorous analysis phase. We analyze market dynamics, growth patterns, and future performance using analytical models and statistical tools.
Top-Down and Bottom-Up Market Sizing Approaches
- Top-Down Approach – Starts with global market size and distributes it across segments using macro-level trends and established proportions.
- Bottom-Up Approach – Aggregates company-level and country-level revenue data to build regional and global market estimates.
These two approaches are cross-validated to remove inconsistencies and ensure accurate market estimation.
Forecasting Models and Market Dynamics Analysis
- Time-Series Analysis – Models historical trends, seasonality, and demand cycles.
- Econometric and Judgmental Forecasting – Combines economic models with expert-driven adjustments.
- Delphi Method – Uses iterative expert input to generate balanced market forecasts.
Data Triangulation and Validation
- Multi-source cross-verification of all data points
- Use of quantitative and qualitative validation techniques
- Sample validation through expert and stakeholder feedback
Market Analysis and Sizing Estimation
- Detailed segmentation analysis
- Competitive landscape evaluation
- Revenue modeling using TAM, SAM, and SOM frameworks
Quality Assurance and Final Review
- Data accuracy and consistency checks
- Content, language, and structure review
- Client-specific customization and refinement
Continuous Improvement in Methodology
We continuously refine our research methodologies based on evolving market conditions, client feedback, and technological advancements. This ensures our research remains accurate, relevant, and aligned with industry standards.
Age-related Macular Degeneration (AMD) Market Report Scope & Segmentation
| Attributes | Details |
|---|---|
| Market Size (Current)Current market valuation | US$ 12.45 Billion in 2026 |
| Market Size (Forecast)Projected market valuation | US$ 24.03 Billion in 2035 |
| Growth RateCompound Annual Growth Rate | CAGR of 7.5% from 2026 to 2035 |
| Forecast PeriodAnalysis timeline | 2026 – 2035 |
| Base YearReference year for analysis | 2025 |
| Historical Data AvailablePast market data availability | Yes |
| Regional ScopeGeographical coverage | Global |
| Segments CoveredMarket segments analyzed | By Drug Type
By Disease Type
By Distribution Channel
|
Leading companies covered in this report
- Regeneron
- Novartis
- F. Hoffmann-La Roche
- Bayer
- Apellis Pharmaceuticals
- Iveric Bio (Astellas)
- Outlook Therapeutics
Frequently Asked Questions
Common questions about this report
The study period covers historical insights and forecast projections for the period 2026-2035.
The global Age-related Macular Degeneration (AMD) Market market is expected to grow at a CAGR of 7.5% during the forecast period 2026-2035.
The report offers comprehensive market segmentation analysis across key categories and sub-segments relevant to the industry, along with regional and competitive insights.
The market is projected to reach 24.03 Billion by 2035.
Regeneron, Novartis, F. Hoffmann-La Roche, Bayer, Apellis Pharmaceuticals, Iveric Bio (Astellas), Outlook Therapeutics.
North America, Europe, and Asia Pacific are key regions covered in the report, including regional trends, market share, and growth opportunities.
Growing demand, technological advancements, changing consumer preferences, and increasing investments are some of the major factors supporting the growth of the Age-related Macular Degeneration (AMD) Market market.
Yes, the report includes company profiling, competitive landscape analysis, strategic developments, mergers & acquisitions, product launches, and market positioning of leading industry participants.
The report is prepared using a combination of primary research, secondary research, expert interviews, industry databases, company annual reports, and proprietary market analysis models.
Yes, report customization options are available based on specific business objectives, geographic focus, competitive benchmarking requirements, and additional market segmentation needs.
Yes, the report is available in both PDF and Excel formats. The Excel file includes all market data tables, forecasts, and segment-wise data for easy analysis.
Yes, you can request a free sample report which includes an overview, table of contents, and sample data pages to help you evaluate the report before making a purchase decision.
About the Author
Market research expert with years of industry experience

Dipali Bhingare serves as the Market Research Director at Econ Market Research. With a focus on translating complex global economic shifts into actionable business intelligence, she oversees the strategic direction of comprehensive market studies. Her work empowers organizations to navigate volatile industries through data-driven forecasting and deep-dive competitive analysis.










